跳至主要内容
临床试验/NCT02585583
NCT02585583已完成不适用

Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2015年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
8
试验地点
2
主要终点
Minimun effective dose (presence/absence of visible MRI thalamotomy)

研究概览

简要总结

The gamma knife radiosurgical thalamotomy to treat many movement disorders is recently becoming a new and well defined treatment paradigm.

The CyberKnife if compared to the frame-based radiosurgery, is a pain free procedure which offers the advantage of a better patient's compliance by avoiding local anaesthesia and the discomfort due to wearing the frame for the period of time needed for the whole procedure.

Unfortunately the subtle but substantial differences about the 3D dose distribution and the dose fall-off features between GK and CK made mandatory investigations about the effectiveness and the safety when the cyberknife is used.

Particularly the minimum effective and safety dose have to be defined yet A previous study (NCT02095600) failed in demonstrating the efficacy of 75 Gy, 80 Gy, 90 Gy.

The aim of the present study is to investigate about the effectiveness of 100 Gy, 120 Gy, 130 Gy and 140 Gy.

The safety and the targeting methodology will be also in investigated.

详细描述

BACKGROUND The stereotactic lesioning of thalamus and basal ganglia for the treatment of tremor is a well-known procedure which, before the introduction of deep brain stimulation ( DBS), was usually performed using stereotactic surgical procedures.[16] Consistent positive experience in functional radiosurgery using the Gamma Knife or linear accelerators was reported since the first report by Leksell in 1951.[4, 8, 11, 13, 14, 17, 18, 19, 21, 24, 25, 26, 27] CyberKnife (CK), (Accuray Inc., Sunnyvale, California, USA) allows a real frameless stereotactic radiosurgery of recognizable intracranial targets such as arteriovenous malformations (AVMs), tumours, and trigeminal nerve for the treatment of trigeminal neuralgia.[1, 2, 3, 7, 9, 23] When compared to the frame-based radiosurgery , frameless radiosurgery is a pain free procedure which offers the advantage of a better patient's compliance by avoiding local anaesthesia and the discomfort due to wearing the frame for the period of time needed for the whole procedure.

The present literature on functional frame-based radiosurgery (mainly based on Gamma Knife treatments) shows that, while a mean dose of 140 Gy has been effectively used, toxicity increases with higher doses. Moreover the minimal effective dose has never been reported [8, 10, 15, 25 ].

Based on the fact that the 3D dose distribution with Gamma Knife shows some subtle but substantial differences with the Cyberknife, the investigators chose a lower prescription dose compared to the literature data when performing our first attempts to treat movement disorders.

Particularly the prescription dose as the minimum effective dose for a functional disorder such as trigeminal neuralgia was identified.

At that time no previous CyberKnife experiences had been reported. The first two patients treated at our Institution by using these lower treatment doses (75 and 90 Gy respectively) [28] had remarkably positive results thus bringing us to consider the real relative effectiveness of low doses.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients affected by severe upper limb tremor refractory to medical therapy and who are less than optimal candidate for a deep brain stimulation (DBS) procedure.
  • Age ≥ 18 years old
  • Refusal of DBS procedure
  • Written consent

排除标准

  • Pregnancy
  • CT/MRI contraindication
  • Illiteracy

结局指标

主要结局

Minimun effective dose (presence/absence of visible MRI thalamotomy)

时间窗: 18 months

The aim of this study is to define the minimum effective dose to obtain a tremor control

次要结局

  • Targeting validation (post treatment thalamotomy merge the target plan)(18 months)
  • Toxicity (according to NCI CTCAE v4.0)(24 months)

研究者

发起方
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验